Search research articles
Contact Us
Filters
Showing results (401-410 of 1,623) with videos related to
Page
of 163
Sort By:
Current Opinion in Oncology
|
October 1, 1992
Systemic therapy for gynecologic cancer
M Markman
Cancer Investigation
|
January 1, 1995
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the public
M Markman
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
Supportive care
M Markman
Cancer Investigation
|
January 1, 1994
When regulatory requirements conflict with ethical study design: the case of oral ondansetron
M Markman
Gynecologic Oncology
|
June 1, 1994
Resetting the CA-125 range for a complete response to chemotherapy: why?
M Markman
Current Oncology Reports
|
August 28, 2012
Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial
Maurie Markman
Dental Economics - Oral Hygiene
|
May 1, 1974
Preventing laboratory snafus
S Markman
Current Oncology Reports
|
February 19, 2005
Care of pediatric cancers in the developing world: should this be a societal priority?
Maurie Markman
Current Oncology Reports
|
December 22, 2004
'Flat-fixed dosing' of chemotherapy: a concept whose time has come?
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
August 10, 2004
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Maurie Markman
Page
of 163
Search research articles
Search
Showing results (401-410 of 1,623) with videos related to
Sort By:
Page
of 163
Current Opinion in Oncology
|
October 1, 1992
Systemic therapy for gynecologic cancer
M Markman
Cancer Investigation
|
January 1, 1995
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the public
M Markman
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
Supportive care
M Markman
Cancer Investigation
|
January 1, 1994
When regulatory requirements conflict with ethical study design: the case of oral ondansetron
M Markman
Gynecologic Oncology
|
June 1, 1994
Resetting the CA-125 range for a complete response to chemotherapy: why?
M Markman
Current Oncology Reports
|
August 28, 2012
Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial
Maurie Markman
Dental Economics - Oral Hygiene
|
May 1, 1974
Preventing laboratory snafus
S Markman
Current Oncology Reports
|
February 19, 2005
Care of pediatric cancers in the developing world: should this be a societal priority?
Maurie Markman
Current Oncology Reports
|
December 22, 2004
'Flat-fixed dosing' of chemotherapy: a concept whose time has come?
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
August 10, 2004
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Maurie Markman
Page
of 163